Your session is about to expire
← Back to Search
Bevacizumab + Niraparib for Ovarian and Endometrial Cancer (ARID1A Trial)
ARID1A Trial Summary
This trial tests how well a combo of two drugs treat ovarian or endometrial cancer with an ARID1A mutation. Effects are studied.
ARID1A Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowARID1A Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ARID1A Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer is advanced but localized, and can potentially be cured.I have never been treated with a PARP inhibitor, including niraparib.You are expected to live for more than 12 weeks.I have had a bone marrow or double umbilical cord blood transplant.I am fully active and can carry on all my pre-disease activities without restriction.I cannot take pills by mouth or have stomach issues affecting medication absorption.I haven't had any other cancers in the last 5 years that could affect my survival.I have not had major surgery in the last 4 weeks.I do not have active heart disease or uncontrolled high blood pressure.I've had signs or symptoms of a bowel blockage in the last 6 weeks.I have lasting side effects from cancer treatment, but not hair loss.I have brain metastases that are causing symptoms and are not under control.I have not had bleeding problems or hemorrhagic disorders in the last 6 months.I can take pills and my body can absorb them.Your disease can be measured using specific medical guidelines.My endometrial or ovarian cancer has worsened and has ARID1A mutations.I have a stored sample of my tumor available.I have healed from major surgeries without open wounds or ulcers.I have a history of or signs pointing to myelodysplastic syndrome or acute myeloid leukemia.I am a woman who can have children and I am not pregnant.I have not had radiotherapy in the last 2 weeks.I do not have any serious, uncontrolled health issues or infections.I am a woman aged 18 or older.I have not had a stroke or mini-stroke in the last 6 months.My heart's electrical activity is irregular or I have a family history of long QT syndrome.My cancer has worsened after treatment with a platinum-based drug.My blood, liver, and kidney tests are within normal ranges.
- Group 1: Arm 2: Niraparib and Bevacizumab
- Group 2: Arm 1: Niraparib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are any new volunteers being accepted for this clinical trial?
"According to the clinicaltrials.gov listing, this trial is currently selecting participants. Initially posted on February 1st of 2023, it was most recently updated 6 days later."
Has the FDA authorized Arm 2: Niraparib and Bevacizumab?
"According to our in-house assessment, the safety of Arm 2: Niraparib and Bevacizumab is rated at a 2. This is as there has been some data collected on its safety but none confirming efficacy."
What is the maximum capacity for participants in this trial?
"Affirmative. According to clinicaltrials.gov, this medical study initially posted on February 1st 2023 is currently enrolling participants. 92 individuals are being recruited from a single site for the trial's duration."
Share this study with friends
Copy Link
Messenger